课题基金 / 基金详情

Microfluidic Cartridge for Point-of-Care Hematology Analysis

Microfluidic Cartridge for Point-of-Care Hematology Analysis
用于即时血液学分析的微流控盒
批准号:
10603090
负责人:
Kelly Mabry
金额:
$27.6万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2023
资助国家:
美国
项目状态:
已结题
起止时间:
2023-02-15 至 2024-01-16

项目摘要

项目成果

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Project Summary/Abstract Evaluation for neutropenia and/or thrombocytopenia requires a 5-part white blood cell (WBC) differential with platelet count. Currently, instruments capable of these measurements must be operated in a CLIA-certified laboratory and rely on complex workflows involving multiple reagents, extensive calibration and maintenance, and operation by highly trained personnel. Turnaround times of hours or days delay administration of critical treatments, such as chemotherapy, anti-psychotic medications, and blood transfusions. Cellia Science will address the need for more rapid blood cell differential tests and develop a device to diagnose neutropenia and thrombocytopenia suitable for point-of-care or low-resource settings. This device will implement label-free deep UV imaging combined with microfluidic “blood smear” preparation and cell classification algorithms to perform blood cell differentials. Cellia’s deep UV images are pseudo-colorized and appear similar to Giemsa-stained images, the current gold standard for manual differentials. However, because we are directly detecting the nucleic acids in the cells, our images are inherently quantitative nucleic acid mass maps with subcellular detail and femtogram sensitivity. In Phase I of this project, we will develop a microfluidic sample cartridge prototype, verify its ability to form the desired cell monolayers, and evaluate the accuracy and precision of counts performed using the cartridge with our imaging device prototype. Blood samples will span the clinically relevant range of hematocrit levels to verify device functionality at varying blood viscosities. Accuracy and precision of the device will be evaluated with samples from healthy patients as well as from patients with neutropenia and thrombocytopenia to demonstrate acceptable performance for the target patient population. Successful development of the microfluidic sample cartridge will demonstrate the feasibility of a scalable, robust sample cartridge for point-of-care hematology analysis. Combined with our existing prototype imaging device and analysis algorithms, this will demonstrate the feasibility of the proposed hematology analyzer.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金